Maintenance olaparib plus bevacizumab (bev) in patients (PTS) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (Pfs2) in the phase III PAOLA-1/ENGOT-ov25 trial
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.